About Rani Therapeutics Holdings, Inc.
https://www.ranitherapeutics.comRani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing.
CEO
Talat Imran
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 20
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:3.15M
Value:$4.41M
VANGUARD GROUP INC
Shares:884.61K
Value:$1.24M
NAN FUNG GROUP HOLDINGS LTD
Shares:493.58K
Value:$691.02K
Summary
Showing Top 3 of 44
About Rani Therapeutics Holdings, Inc.
https://www.ranitherapeutics.comRani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $7.26M ▼ | $-5.41M ▲ | 0% | $-0.12 ▲ | $-6.97M ▲ |
| Q2-2025 | $0 ▼ | $10.51M ▼ | $-6.69M ▲ | 0% ▲ | $-0.18 ▲ | $-10.11M ▲ |
| Q1-2025 | $172K ▼ | $12.19M ▼ | $-7.26M ▲ | -4.22K% ▼ | $-0.22 ▲ | $-11.54M ▲ |
| Q4-2024 | $1.03M ▲ | $15.99M ▲ | $-8.95M ▼ | -870.33% ▼ | $-0.27 ▼ | $-14.33M ▼ |
| Q3-2024 | $0 | $11.8M | $-6.78M | 0% | $-0.24 | $-11.13M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.14M ▼ | $10.14M ▼ | $22.11M ▼ | $-7.86M ▼ |
| Q2-2025 | $10.22M ▼ | $16.9M ▼ | $26.05M ▼ | $-5.58M ▼ |
| Q1-2025 | $15.85M ▼ | $24.13M ▼ | $29.47M ▼ | $-3.06M ▼ |
| Q4-2024 | $27.64M ▼ | $36.63M ▼ | $33.14M ▼ | $1.99M ▼ |
| Q3-2024 | $30.4M | $43.54M | $37.77M | $3.12M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.91M ▼ | $-5.06M ▲ | $0 ▼ | $-1.01M ▼ | $-6.07M ▼ | $-5.06M ▲ |
| Q2-2025 | $-6.69M ▲ | $-5.8M ▲ | $5.71M ▼ | $188K ▲ | $105K ▼ | $-5.83M ▲ |
| Q1-2025 | $-7.26M ▲ | $-8.15M ▲ | $18.23M ▲ | $-3.73M ▼ | $6.35M ▲ | $-8.2M ▲ |
| Q4-2024 | $-15.72M ▼ | $-8.65M ▼ | $2.52M ▲ | $5.62M ▼ | $-515K ▼ | $-8.69M ▼ |
| Q3-2024 | $-12.72M | $-8.41M | $469K | $7.7M | $-237K | $-8.54M |
CEO
Talat Imran
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 20
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:3.15M
Value:$4.41M
VANGUARD GROUP INC
Shares:884.61K
Value:$1.24M
NAN FUNG GROUP HOLDINGS LTD
Shares:493.58K
Value:$691.02K
Summary
Showing Top 3 of 44